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Abstract
Objective N6-isopentenyladenosine (iPA) is an intermediate of the mevalonate pathway that exhibits various anti-cancer 
effects. However, studies on its anti-inflammatory activity are scarce and underlying molecular mechanisms are unknown. 
Therefore, we aimed to investigate the ability of iPA to exert anti-inflammatory effects in the human cystic fibrosis (CF) cell 
model of exacerbated inflammation.
Materials and methods TNFα-stimulated CF cells CuFi-1 and its normal counterpart NuLi-1 were pre-treated with increasing 
concentrations of iPA and cell viability and proliferation were assessed by MTT and BrdU assays. The effect of iPA on IL-8 
and RANTES secretion was determined by ELISA, and the activation and expression of signaling molecules and selenopro-
teins were studied by Western blot. To assess the direct effect of iPA on NFκB activity, luciferase assay was performed on 
TNFα-stimulated HEK293/T cells transfected with a NFκB reporter plasmid.
Results We demonstrated for the first time that iPA prevents IL-8 and RANTES release in TNFα-stimulated CF cells and 
this effect is mediated by increasing the expression of the direct NFκB inhibitor IκBα and decreasing the levels of STAT3. 
Consistent with this, we showed that iPA inhibited TNFα-mediated NFκB activation in HEK/293T cells. Finally, we also 
found that iPA improved the levels of glutathione peroxidase 1 and thioredoxin reductase 1 only in CF cells suggesting its 
ability to maintain sufficient expression of these anti-oxidant selenoproteins.
Conclusions Our findings indicate that iPA can exert anti-inflammatory activity especially in the cases of excessive inflam-
matory response as in CF.
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iPA  N6-isopentenyladenosine
Sec-tRNA  Selenocysteine transfer RNA
5-Itu  5-Iodotubercidin
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ADK  Adenosine kinase
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AMPK  AMP-activated protein kinase
tRNA-IPT  tRNA-isopentenyltransferase
DMAPP  Dimethylallyl pyrophosphate
iPAMP  5′-iPA-monophosphate
GPX1  Glutathione peroxidase 1
TR1  Thioredoxin reductase 1
CFTR  Cystic fibrosis transmembrane conductance 
regulator
NFκB  Nuclear factor-κB
STAT  Signal transducer and activator of 
transcription
IκBα  NFκB inhibitorα
JAK  Janus protein tyrosine kinase
ROS  Reactive oxygen species
Introduction
N6-isopentenyladenosine (iPA) is a cytokinin originally 
identified in plants but also present in human cells in a free 
form or as a modified adenosine bound at position 37 of 
selenocysteine transfer RNA (Sec-tRNA) [1, 2]. The addi-
tion of iPA on adenosine is catalyzed by tRNA-isopentenyl-
transferase (tRNA-IPT) using dimethylallyl pyrophosphate 
(DMAPP)—an intermediate of the mevalonate pathway—
as donor of the isoprenoid chain [3]. The tRNA[Ser]Sec is 
co-translationally inserted into selenoproteins at in-frame 
UGA codons and is required to improve fidelity and effi-
ciency of the selenoprotein synthesis [4, 5]. In Xenopus, 
a site-specific mutation eliminating the site of isopente-
nylation in the tRNA[Ser]Sec gene markedly reduced the 
synthesis of the selenoproteins deiodinases [6], whereas in 
transgenic mice expressing iPA-deficient tRNA[Ser]Sec, a 
tissue-specific reduction of selenoprotein synthesis includ-
ing glutathione peroxidase 1 (GPX1) and thioredoxin reduc-
tase 1 (TR1) was observed [7]. A number of evidence has 
shown that iPA induces antiproliferative and pro-apoptotic 
effects in a variety of tumors in vitro and in vivo even though 
its mechanism of action is not yet fully understood [8–10]. 
The existing data report that in human breast cancer cells, 
iPA-induced effects can be mediated by the inhibition of 
the Akt/NFκB cell survival pathway [11] and more recently 
it has been reported that iPA, phosphorylated by adenosine 
kinase (ADK) into 5′-iPA-monophosphate (iPAMP), is able 
to inhibit angiogenesis in vitro and in vivo, triggering the 
AMP-activated protein kinase (AMPK) [12]. However, only 
few studies reported that iPA has some immunomodulatory 
properties being able to selectively expand and directly tar-
get natural killer (NK) cells [13] and reduced mouse ear 
oedema in a murine model of croton oil-induced dermatitis 
[14]. These studies did not investigate in depth the effect 
of iPA in inflammatory response and no studies have ever 
investigated its anti-inflammatory activity in chronic inflam-
matory disease such as CF.
On the basis of the overall considerations, we aimed to 
ascertain the anti-inflammatory activity of iPA using a cystic 
fibrosis (CF) cell model. CF is well known to be a chronic 
inflammatory disease caused by mutations in the gene 
encoding the cystic fibrosis transmembrane conductance 
regulator (CFTR), an ATP-gated chloride channel which is 
expressed, among others, at the apical membrane of epithe-
lial secretory cells of the airways. Loss of functional CFTR 
in airways promotes surface liquid depletion and defective 
mucociliary clearance producing a cruel circle of phlegm 
retention, infection and inflammation leading to pulmo-
nary failure [15]. CFTR-deficient airway epithelial cells are 
characterized by an excessive inflammatory response and 
display signaling abnormalities, especially activation of 
nuclear factor-κB (NFκB) [16] leading to the overexpression 
of epithelial-derived cytokines and chemokines including 
the neutrophilic and macrophage chemoattractants IL-8 and 
RANTES [17, 18].
To study the effect of iPA on CF inflammation, we ana-
lyzed its ability to inhibit chemokine release from both CF 
and non-CF cells, stimulated or not with tumor necrosis fac-
tor α (TNFα) which is a key cytokine in the initiation of 
the early inflammatory process [19]. We used CuFi-1 cells 
derived from a human CF lung homozygous for the deletion 
of phenylalanine 508 in the CFTR protein  (CFTRΔF508/ΔF508), 
and its normal counterpart NuLi-1 (wild type). These non-
cancerous cell models are reported to maintain the ion chan-
nel physiology and retained signal transduction responses 
to inflammatory stimuli expected for the genotypes [20]. 
Moreover, we also investigated the possible mechanism of 
action of iPA by analyzing NFκB, MAPK/ERK, and signal 
transducer and activator of transcription 3 (STAT3) signal-
ing which are among the major pathways involved in CF 
inflammatory response [21, 22]. Finally, since it is known 
that anti-oxidant selenoproteins, such as glutathione peroxi-
dases and thioredoxin reductases, are involved in inflam-
matory process [23, 24], we evaluated the effect of iPA on 
GPX1 and TR1 expression levels in both cell types.
Materials and methods
Drugs and drug treatment
N6-isopentenyladenosine (iPA) (Sigma Aldrich, St. Louis, 
MO, USA) was dissolved in DMSO and added to cell cul-
tures at the indicated concentration and for the indicated 
time. 5-Iodotubercidin (5-Itu) was purchased from Tocris 
Bioscience (Bristol, UK), dissolved in ethanol and added to 
cell cultures at a concentration of 30 nM for 30 min before 
any other treatment. TNFα (R&D Systems, Minneapolis, 
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MN, USA) was added at a concentration of 20 ng/ml (CuFi-1 
and NuLi-1 cells) or 10 ng/ml (HEK 293/T cells) 1 h after 
any other treatment and left for 14 h.
Cell cultures
Cystic fibrosis CuFi-1 cell line, derived from a CF human 
bronchial epithelium homozygous for the CFTR ΔF508 
mutation (American Type Culture Collection, ATCC, 
Manassas, VA, USA) and non-CF cells NuLi-1 [20] were 
grown on human placental collagen type VI-coated flasks 
(Sigma Aldrich, Milan, Italy) in BEGM medium (Clonet-
ics, Lonza, Walkersville, Inc). Human Embryonic Kidney 
(HEK) 293/T cells were cultured in Dulbecco’s modified 
Eagle’s medium (Invitrogen, Carlsbad, CA, USA) supple-
mented with 10% fetal bovine serum, 2 mM L-glutamine, 
penicillin (50 U/mL) and streptomycin (50 µg/mL). Cells 
were incubated at 37 °C in a humidified atmosphere at 5% 
 CO2.
Viability assay
Cell viability was analyzed using the MTT assay. Briefly, 
cells were seeded in 96-well plates at the density of  104/well, 
left to adhere to the plate and then treated with increasing 
concentrations of iPA ranging from 0.1 to 10 μM for CuFi-1 
and NuLi-1, and from 0.1 to 5 μM for HEK 293/T cells for 
24 h and 48 h. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) was added (0.5 mg/ml final con-
centration) to each well and incubated at 37 °C for additional 
4 h. Formazan products were dissolved in 10% Triton X-100, 
0.1 N HCl in 2-propanol. Absorbance was determined at 
595 nm using a microplate reader (Bio-Rad Laboratories srl, 
MI, Italy) as previously described [25].
Proliferation assay
Cell proliferation was evaluated using a colorimetric bro-
modeoxyuridine (BrdU) cell proliferation ELISA kit (Roche 
Diagnostics, Milan, Italy). In brief,  104 cells were seeded 
into 96-well plates and left to adhere to the plate. Cells were 
then treated with increasing concentrations of iPA (0.1 to 
10 μM) for 24 and 48 h. BrdU (10 μM final concentration) 
was added for the last 16 h. After the incubation period, 
the medium was removed and the ELISA BrdU immunoas-
say was performed following manufacturer’s instructions. 
The colorimetric reaction was stopped with  H2SO4, and 
the absorbance was measured at 450 nm using a microplate 
reader (Bio-Rad Laboratories, Milan, Italy) as previously 
described [26].
Determination of IL‑8 and RANTES release
For cytokine determinations, 1 × 106 cells were plated and 
left to adhere to the plate. Then, cells were preincubated 
with iPA for 1 h and/or 5-Itu and then stimulated with TNFα 
for a further 14 h. Cultured media were then collected, cen-
trifuged for 5 min at 2000 rpm and the production of IL-8 
and RANTES was determined by enzyme-linked immuno-
sorbent assay (ELISA) (R&D Systems) following manufac-
turer’s instructions. The used ELISAs were sensitive at 3.5, 
and 2 pg/ml, respectively. Cytokine concentration in cell-
free media was calculated as pg/ml/106 cells.
Western blot analysis
Cells were collected by centrifugation, washed twice with 
PBS and resuspended in RIPA buffer (NaCl 150 mM, 1% 
triton X-100 pH 8.0, 0.5% sodium deoxycholate, 0.1% SDS, 
50 mM Tris, pH 8.0) at 4 °C, then centrifuged at 13,000 rpm 
for 30 min. Supernatants were collected and protein con-
centrations were determined by Bio-Rad protein assay. 
Equal amounts of protein extracts (30 µg) were boiled in 
Laemmli’s buffer, fractioned on 12% SDS–PAGE and then 
transferred to nitrocellulose membranes (Amersham GE 
Healthcare, Milan, Italy). Membranes were blocked in 
TBS-T (50 mM Tris, 135 mM NaCl, and 5 mM KCl, 0,1% 
Tween-20) containing 5% non-fat dry milk, then incubated 
overnight at 4 °C with anti-phoshoERK 1/2, anti-phoshoS-
TAT3 (Tyr 705), anti-IKKα, anti-IKKβ, anti-IKKγ or anti-
IkBα (all from Cell Signaling Technology Inc). To evaluate 
selenoprotein expression, anti-GPX1 and anti-TR1 (Abcam, 
Cambridge, UK) were also used. After three washes, blots 
were probed with mouse or rabbit horseradish peroxidase-
conjugated secondary antibodies (Cell Signaling Technol-
ogy) for 1 h at room temperature and then developed using 
the ECL chemiluminescence system (Amersham GE Health-
care). Finally, membranes were stripped and re-probed with 
total anti-ERK1/2, (Cell Signaling Technology) and anti 
α-tubulin used as loading controls (Abcam). Results are 
the mean of three independent experiments. Immunoreac-
tive bands were quantified using Quantity One I-D analysis 
software (Bio-Rad).
Cell transfection and NFκB activity
Transfection of HEK 293/T was carried out using  CaPO4 
method as already reported [26]. All transfections included 
the reporter plasmid (IgκB-Luc), an internal control TK-
renilla, and a supplemental empty vector to maintain the 
total amount of transfected DNA constant in each cell cul-
ture. 24 h after transfection, cells were pre-treated with iPA 
(2.5–5 µM) for 1 h and then stimulated with TNFα. After 
4 h, cells were lysed using a Luciferase Passive Lysis buffer 
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(P/N E1941, from Promega Corporation). Cell lysates were 
then harvested and assayed using the Dual-Glo Luciferase 
Reporter Assay System (Promega). Luciferase activity was 
measured using a multiplate reader  (GloMax® 96 Microplate 
Luminometer, Promega), and values were normalized to the 
Renilla luciferase activity [27].
Statistical analysis
Measurements were performed in triplicates, unless other-
wise stated. Values were expressed as means of three inde-
pendent experiments with three replicates each ± SD. Sta-
tistical differences between the treatments and the controls 
were evaluated by the Student’s t test. P values less than 0.05 
were considered statistically significant.
Results
Cytotoxic activity of iPA in CF and non‑CF cells
To determine the anti-inflammatory properties of iPA, first 
we investigated its cytotoxic activity in CF cells (CuFi-1) 
and non-CF cells (NuLi-1). Cells were treated with increas-
ing concentrations of iPA from 0.1 to 10 µM for 24 and 
48 h. MTT and BrdU assays were performed to evaluate 
cell viability and cell proliferation, respectively. Mitomycin 
C was used as a positive control. Figure 1 shows that iPA 
induced a general dose- and time-dependent inhibition of 
cell viability (left panels) and proliferation (right panels) 
in both CuFi-1 and NuLi-1 cells. Particularly iPA did not 
affect cell viability in the concentration range between 0.1 
and 5 µM at 24 h of treatment in CuFi-1 cells (Fig. 1A), 
whereas it decreases cell viability of 37% at 5 µM and 48 h. 
CuFi-1 cell proliferation (Fig. 1A) was markedly inhibited 
by iPA (64% at 24 h and 5 µM), and at 10 µM only about 
16% of cells were dividing. Concerning the results obtained 
in cell normal counterpart (NuLi-1, Fig. 1B), we observed a 
statistically significant reduction of cell growth starting from 
2.5 µM concentration at 48 h of treatment, indicating that 
normal bronchial epithelial cells were slightly more suscep-
tible to iPA-mediated inhibition of cell growth compared to 
CF cells. However, as in the case of CuFi-1 cells, iPA did not 
induce any significant cytotoxic effect until 5 µM at 24 h of 
treatment. Therefore, concentrations not exceeding 5.0 µM 
and a time-treatment below 24 h were chosen to study the 
potential anti-inflammatory effects of iPA.
iPA selectively inhibits cytokine release in CF 
and non‑CF cells
CF cells lacking a functional CFTR are characterized by 
higher production of chemokines able to attract neutrophils 
and macrophages in the airways [17, 18, 21, 28]; there-
fore, the activity of iPA was determined in both CuFi-1 
and NuLi-1 cells by analyzing IL-8 and RANTES release 
in the absence of pro-inflammatory mediators and after 
TNFα stimulation using two concentrations of iPA (1.0 and 
2.5 µM). Results (Fig. 2A) indicated that iPA was able to 
reduce significantly chemokine production from 1.0 µM and 
reached the highest effect at 2.5 µM by inhibiting the secre-
tion of IL-8 (50%) and RANTES (32%) in CF cells stimu-
lated with TNFα. Interestingly, a dose-dependent inhibition 
of IL-8 (until 23% at 2.5 µM) and RANTES (until 21% 
at 2.5 µM) was also observed in resting cells. The results 
obtained in NuLi-1 cells (Fig. 2B), also highlighted a sig-
nificant iPA-mediated reduction of IL-8 and RANTES secre-
tion by an average of 33% and 63%, respectively, at 2.5 µM 
especially in TNFα-treated cells. It appears that in normal 
cells iPA is most effective in reducing RANTES production 
compared to CuFi-1 cells and its inhibitory effect is higher in 
the presence of pro-inflammatory stimuli. Of note, the effect 
of iPA is highly specific since the treatment of both cell lines 
with 5-Itu, an ADK inhibitor that was reported to phospho-
rylate and activate iPA inside cells [12], completely reverted 
the inhibitory effects of iPA in both CF and non-CF cells. 
Altogether, these results indicate that iPA decreases IL-8 
and RANTES release and this effect is particularly elevated 
in the presence of inflammatory response or in steady state 
condition of reactive cells as in the case of CF cells exhibit-
ing higher basal levels of both proteins.
NFκB and STAT3 signaling pathways are differently 
regulated by iPA in CF and non‑CF cells
NFκB, MAPK/ERK, and STAT3 pathways plays a cen-
tral role in the inflammatory signaling cascades leading 
to cytokine and chemokine production and some studies 
have demonstrated that NFκB and MAPK/ERK pathways 
are intrinsically overactivated in various CF cell lines [22, 
29, 30]; therefore, to assess whether the effects of iPA 
could be a result of the modulation of these pathways, 
CuFi-1 cells were incubated with iPA 2.5 µM and then the 
main molecular targets of MAPK/ERK, NFκB and STAT3 
pathways were analyzed. As shown in Fig. 3A, iPA caused 
a reduction of ERK phosphorylation only at 5 min and 
4 h of treatment in CuFi-1 cells under TNFα stimulation, 
while no significant changes were observed at all other 
time points and in the absence of TNFα (Fig. 3B), suggest-
ing that MAPK/ERK pathway can be slightly modulated 
by iPA in the presence of TNFα-induced inflammation and 
is not preferentially involved in iPA-mediated reduction of 
chemokine secretion in the presence of the innate hyper-
inflammatory status of CuFi-1 cells. On the contrary, a 
relevant reduction of STAT3 activity was found either in 
TNFα-stimulated CF cells at 5 min and from 30 min to 
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1 h of iPA treatment (Fig. 3A, B), or in CF cells treated 
with iPA from 15 min to 4 h (Fig. 3B). In the same experi-
mental conditions, the treatment with iPA also negatively 
affected the background protein expression levels of the 
NFκB-regulatory subunits IKKα and IKKβ at a longer 
time exposure (from 1 to 4 h, Fig. 3b), whereas IKKγ 
subunit was inhibited at 5 min and 1 h (Fig. 3). As con-
cerns the direct NFκB inhibitor IκBα, we also observed a 
marked and statistical significant increase of its expres-
sion starting from 5 min and until 30 min (Fig. 3a) in both 
TNFα-stimulated or -unstimulated CuFi-1 cells (Fig. 3a, 
b), thus proposing that iPA, by increasing IκBα expres-
sion and down-regulating IKKs subunits is able to inhibit 
NFκB pathway.
To assess whether a similar mechanism of action was 
responsible for the iPA-induced effects in normal human 
bronchial epithelial cells, NuLi-1 were stimulated with 
TNFα and treated with iPA as in CuFi-1 cells, and analyzed 
for the expression of proteins whose expression was found 
markedly modulated in CF cells. Results shown in Fig. 4 
indicate that similarly to CF cells, iPA reduced the phosho-
rylation of STAT3 in the absence of any pro-inflammatory 
stimulus starting from 5 min and for all over the treatment 
time. However, we did not observe significant changes 
in STAT3 activation following iPA treatment in TNFα-
stimulated NuLi-1 cells except for 4 h of treatment. More-
over, as in CuFi-1 cells, iPA increased significantly IκBα 
expression (Fig. 4b) at all time points both in the presence or 
Fig. 1  Effects of iPA on cell viability and proliferation in CuFi-1 
and NuLi-1 cells. CuFi-1 (a) and NuLi-1 (b) cells were treated with 
increasing concentrations of iPA for 24 and 48 h. Cell viability was 
determined by MTT assay, whereas cell proliferation was detected 
using a BrdU incorporation assay (see materials and methods for 
details). Mytomycin C at a concentration of 3 µM (MMC 3) was used 
as positive control. Histograms report the percentage of viable and 
proliferating cells compared to controls (time zero, 100%). Data are 
shown as mean ± SD of three independent experiments each done in 
triplicates.*P < 0.05 and **P < 0.01 vs control
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absence of TNFα treatment, thus indicating that iPA can act 
by negative modulating key inflammatory proteins involved 
in the NFκB and STAT3 pathways, even though the iPA-
induced effect is quite different in CF and non-CF cells.
iPA reduces NFκB activity and IL‑8 production 
in HEK/293T cells
The data here presented have underlined that iPA can act 
as an anti-inflammatory drug in bronchial epithelial cells 
regulating particularly the NFκB pathway. To further inves-
tigate this effect, we analyzed the effects of iPA treatment 
on NFκB transcriptional activity. We used HEK/293T cells 
transiently transfected with a NFκB reporter plasmid, having 
five tandem copies of the human NFκB binding site fused to 
luciferase gene [31]. We chose to study the effects of iPA at 
sub-toxic concentrations, thus we carried out experiments to 
determine whether iPA could have a cytotoxic effect in the 
concentration range used in CF and non-CF cells. Results 
clearly show that there was not any inhibition of both cell 
proliferating ability and viability at all concentrations tested 
and for a time-treatment of 24 h (Fig. 5a). On the basis of 
these results, we analyzed NFκB activity after 6 h of treat-
ment with iPA in the presence or not of TNFα stimulation. 
Results indicate that iPA was able to reduce drastically 
the TNFα-induced activation of NFκB in a concentration-
dependent manner (Fig. 5b). As expected, this effect was 
also associated to a significant reduction of IL-8 in the same 
cell line (Fig. 5c). The inhibitory trend of this cytokine 
release was comparable to NFκB-dependent transcription 
Fig. 2  Effect of iPA on IL-8 and RANTES release in TNFα-
stimulated and -unstimulated CuFi-1 and NuLi-1 cells. Cells were 
treated or untreated (controls, ctr) with iPA at indicated concentra-
tions and then stimulated or not with TNFα as reported in Mate-
rials and Methods. IL-8 and RANTES levels were then detected in 
CuFi-1 cells (a) and in NuLi-1 cells (b). The iPA-induced effect on 
chemokines release was reverted by pretreating CuFi-1 and NuLi-1 
cells with the ADK inhibitor 5-iodotubercidin (5-Itu, 30  nM for 
30  min before iPA treatment). Data are expressed as mean ± SD of 
three independent experiments, each done in duplicates.*P < 0.05 and 
**P < 0.01 vs the corresponding control
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activation and was particularly evident in cells stimulated 
by TNFα (Fig. 5). Altogether, these data corroborate our 
hypothesis that iPA could exert its anti-inflammatory effect 
through inhibiting NFκB activity and this leads to the reduc-
tion of IL-8.
iPA positively modulates GPX1 and TR1 expression 
in CF cells
iPA, as an intermediate of the isoprenoid pathway, plays a 
crucial role in protein translation, and its lacking can impair 
selenoprotein synthesis including GPX1 and TR1 which are 
proteins involved in cell oxidative stress response and anti-
inflammatory process [6, 7, 23, 24]. Therefore, we finally 
investigated whether iPA could affect protein expression 
levels of GPX1 and TR1. By comparing iPA-mediated 
effects in the two cited cell lines, we observed that iPA strik-
ingly increased the expression of GPX1 and TR1 in CuFi-1 
cells characterized by an intrinsic inflammation also in the 
absence of any infection (Fig. 6). The GPX1 increase starts 
from 15 min of iPA treatment and persists until 30 min, 
while TR1 induction was retained until 1 h. In contrast, in 
non-CF cells, we showed only a slight but not statistical 
significant enhancement of GPX1 and no variations in TR1 
expression were found. Of note, GPX1 background level of 
CuFi-1 cells was lower than its normal counterpart NuLi-
1, thus suggesting that CFTR dysfunction can affect GPX1 
levels and that iPA can partially compensate for this decrease 
by promoting GPX1 expression.
Discussion
Findings of our study show that iPA inhibits the inflam-
matory response reducing IL-8 and RANTES production 
through a mechanism of action involving primarily the 
downregulation of the NFκB and STAT3 pathways in a 
CF cell model characterized by exacerbated inflammation. 
Despite the increasing literature on the anti-cancer effects 
of iPA in a broad variety of tumors, very little is known 
about the possibility that iPA could modulate inflammatory 
process. Some data suggested an anti-inflammatory activity 
of the compound in a murine model of croton oil-induced 
mouse edema [14] and in a Car-S mouse model of 12-O-tet-
radecanoylphorbol-13-acetate (TPA)-induced oxidative 
stress [32] but in both cases authors did not provide insights 
about the underlying mechanism of action. Previous studies 
from our group also showed that iPA can exert some immu-
nomodulatory properties in IL-2 activated human primary 
natural killer (NK) cells [13], however no data are available 
on its anti-inflammatory action in CF disease. To investi-
gate this issue, we analyzed the effect of iPA on IL-8 and 
RANTES release in CuFi-1  (CFTRΔF508/ΔF508) and NuLi-1 
cell lines (CFTR wild type) which are both telomerase-
immortalized airway cells, characterized by the ability to 
constitute a polarized monolayer with a transepithelial activ-
ity that mimics the behavior of CF airway epithelial cells 
in vivo [20]. CuFi-1 cells show overexpression of a number 
of signal transduction pathways including MAPK/ERK and 
NFκB that are responsible for the overactivation of several 
inflammatory and oxidative stress genes such as IL-6, IL-8 
and RANTES [33, 34]. The use of these two cell systems 
allowed us to ascertain whether the effect of iPA was related 
to the CFTR mutation or was a common anti-inflammatory 
effect. Indeed, by treating both CF and non-CF cells with 
iPA, we found that iPA was highly efficacious in reducing 
IL-8 and RANTES secretion in both CuFi-1 and NuLi-1 
cells but to a different extent. iPA was most efficacious in 
reducing IL-8 in CuFi-1 cells, whereas a greater decrease 
of RANTES secretion was observed in TNFα-stimulated 
NuLi-1 cells. A possible explanation for this selective inhibi-
tion is that signaling transduction pathways may have altered 
functionality in primary CF cells compared to normal cells 
thus contributing differently in reducing chemokine secre-
tion. In fact, chemokines require activation of NFκB path-
way but it has been shown that RANTES and IL-8 gene 
expression are differentially regulated by NFκB in CF vs 
normal epithelia [35–38]. Di Mango et al. [36] proposed 
that increased levels of IL-8 secreted by CF IB3 cells may 
be a result of greater amounts of endogenous nuclear NFκB 
found in these cells compared to CFTR-corrected cells. 
Moreover, we demonstrated that iPA was also able to slow 
down the NFκB pathway by increasing its direct inhibitor 
IκBα in both CF and TNFα-stimulated non-CF cells, thus 
suggesting that iPA can act as a NFκB inhibitor decreasing 
the production of the pro-inflammatory chemokines IL-8 
and RANTES. From this point of view, our results may have 
therapeutic implications since IL-8 is the most abundant 
chemokine found in broncoalveolar fluid of CF patients [39]. 
It has been shown that pro-inflammatory genes, including 
IL-8 and RANTES, are activated following infection with 
Pseudomonas aeruginosa in CF lung [40, 41] substantially 
contributing to the hyper-inflammatory status of the disease. 
Even though we do not provide direct evidence on NFκB 
expression and distribution inside cells, our data indicat-
ing increased levels of IκBα following the treatment with 
iPA suggest that NFκB could be retained in the cytoplasm 
through its association with IκBα being not allowed to trans-
locate into the nucleus and activate genes controlling the 
inflammatory process. According to this hypothesis, our 
data indicated a marked reduction of NFκB transcriptional 
activity after iPA treatment in HEK/293T cells. On the other 
hand, TNFα we used to induce inflammation has been shown 
to mediate directly NFκB activation through the phospho-
rylation and subsequent degradation of IκBα [42].
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Beside the primary role of the NFκB pathway in inflam-
matory response, other signaling transduction pathways, 
such as MAPK/ERK pathway, are involved in exaggerated 
cytokine and chemokine release in CF [21, 30]. Unex-
pectedly, we found that iPA did not cause high variations 
in ERK phosphorylation in CF cells thus suggesting that 
other transduction factors could be responsible for iPA-
induced effects. Recently, it has been proposed a role for 
STAT3 in regulating CF-related inflammation since the 
overproduction of IL-8 and CXCL1 chemokines is partially 
controlled by ER stress in a STAT3-dependent manner [22]. 
STAT3 plays a central role in the inflammatory signaling 
cascades triggered by LPS, INFγ and other cytokines [43, 
44]. Binding of cytokines to specific receptors activates 
phosphorylation of Janus kinase (JAK) receptor family that 
in turns phoshorylates STAT3 and promotes its translocation 
into the nucleus, where it binds to specific gene promoter 
sequences and inhibits the production of cytokines such as 
endotoxin-inducible expression of TNFα, IL-6, IL-1β, IL-8 
and RANTES [43, 44]. Starting from these observations, we 
investigated STAT3 signaling in CF and non-CF cells evi-
dencing that the TNFα -induced phosphorylation of STAT3 
was inhibited by iPA in CFTR-mutated cells whereas in nor-
mal cells iPA-mediated activation of STAT3 was reduced in 
basal conditions but not substantially affected after the treat-
ment with TNFα. This observation could be explained by the 
fact that background STAT3 levels are higher in CuFi-1 cells 
compared to NuLi-1 cells, suggesting an overactivation of 
this pathway in CF cells. Therefore, we speculate that iPA 
Fig. 3  Effects of iPA on MAPK/ERK, STAT3 and NFκB pathways in 
TNFα-stimulated and -unstimulated CuFi-1 cells. Cells were treated 
(+) or not (−) with 2.5  µM iPA in presence (+) or absence (−) of 
TNFα for the indicated time points A: Representative western blots 
on protein extracts showing the effects of iPA on pERK, pSTAT3 
and key cell signaling proteins of the NFκB pathway compared to 
untreated control cells (ctr, time zero). Tubulin was used as loading 
control. b Densitometric analysis showing relative band intensity 
means (arbitrary units, a.u.) ± SD of three independent experiments. 
Statistical analysis of iPA data: *P < 0.05 and **P < 0.01 vs the cor-
responding control
◂
Fig. 4  Effects of iPA on 
pSTAT3 and IκBα in TNFα-
stimulated and -unstimulated 
NuLi-1 cells. Cells were treated 
(+) or not (−) with 2.5 µM iPA 
in presence (+) or absence (−) 
of TNFα for the indicated time 
points. a Representative West-
ern blots showing the effects 
of iPA on pSTAT3 and IκBα 
compared to untreated control 
cells (ctr, time zero). Tubulin 
was used as loading control. b 
Densitometric analysis showing 
relative band intensity means 
(arbitrary units, a.u.) ± SD of 
three independent experiments. 
Statistical analysis of iPA data: 
*P < 0.05 and **P < 0.01 vs the 
corresponding control
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could exert anti-inflammatory activity in CF cells by target-
ing selectively NFκB and STAT3 pathways which are both 
altered in these cells compared to normal cells.
In this study, we also show that the block of ADK activ-
ity with its inhibitor 5-Itu counteracts the effects of iPA on 
chemokines secretion clearly indicating that phosphorylation 
of iPA into iPAMP is essential for its biological activity. 
This is in agreement with our previously reported data in 
other physiopathological cell contexts [10, 12] and suggests 
that iPA, behaving as an AMP mimetic in CF and non-CF 
epithelial cells, could activate the adenosine monophosphate 
(AMP)-activated protein kinase (AMPK) which plays a cen-
tral role in the regulation of inflammatory response includ-
ing pulmonary emphysema [45–47]. Of note, AMP-activated 
kinase (AMPK) is also an ubiquitous metabolic sensor that 
inhibits CFTR and as highlighted by Hallows et al. [48], the 
pharmacologic AMPK activation inhibited inflammatory 
mediator secretion in both wild type- and ΔF508-expressing 
cells, thus suggesting a iPA-mediated molecular mechanism 
that needs further investigations. Notably, iPA is present 
Fig. 5  Effects of iPA on HEK293/T cells. a Cells were treated with 
increasing concentrations of iPA for 24  h. Cell viability and prolif-
eration were determined by MTT and BrdU assays and are expressed 
as percent of controls (100%). b HEK293/T cells were transiently 
transfected with a NFκB reporter plasmid and an internal control 
plasmid TK-Renilla. After 24 h, cells were preincubated for 1 h with 
iPA and treated or not (control, ctr) with TNFα for additional 4 h to 
activate NFκB. Results are expressed as fold activation of NFκB with 
respect to untreated cells. c Cells were treated with the indicated con-
centrations of iPA and then stimulated or not with TNFα as above. 
IL-8 production was detected as described in Materials and Methods. 
Results are all reported as mean ± SD of three independent experi-
ments, each done at least in duplicates. *P < 0.05 and **P < 0.01 vs 
control
Fig. 6  Effects of iPA on Glutathione peroxidase 1 (GPX1) and thiore-
doxin reductase 1 (TR1) expression in CuFi-1 and NuLi-1 cells. a 
Cells were treated (+) or not (−) with 2.5 µM iPA for the indicated 
time points and representative Western blots are showed compared to 
untreated control cells (ctr). Tubulin was used as loading control. b 
Densitometric analysis showing relative band intensity means (arbi-
trary units, a.u.) ± SD of three independent experiments. *P < 0.05 
and **P < 0.01 vs the corresponding control
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in human tissues where it interferes with cell metabolism 
affecting cell survival, proliferation and apoptosis by modu-
lating the isoprenoid pathway—a metabolic pathway leading 
to cholesterol biosynthesis—referred to is itself a deriva-
tive [3, 10]. Many alterations of CF cell signaling including 
decreased expression of nitric oxide synthase 2 (NOS2), 
reduced function of signal transducer and activator of tran-
scription 1 (STAT1) and reduced function of Rab GTPase 
have been directly attributed to perturbed cholesterol homeo-
stasis [49], thus it is also possible that intracellular increased 
levels of iPA could improve these signaling abnormalities. 
However, it is unlikely that the anti-inflammatory effect of 
iPA could be ascribable to the regulation of the mevalonate 
pathway, since the pre-treatment of CuFi-1 cells with meva-
lonate or lovastatin, which is a HMGCoA reductase inhibi-
tor, failed to revert or interfere with iPA-induced effect on 
chemokine production (data not shown). Finally, iPA plays 
a crucial role in protein translation, since its lacking can 
impair selenocysteine RNA maturation and then selenopro-
tein synthesis [6, 7]. Consistent with this, we showed that 
iPA is highly efficacious at inducing the expression of anti-
oxidant GPX1 and TR1 selenoproteins in CF cells, suggest-
ing that iPA could exert its anti-inflammatory effect also by 
maintaining adequate expression levels of selenoproteins. 
Our findings are in agreement with Dassano et al. [32] who 
showed that in breast cancer and HL-60 cells induced to 
differentiate in neutrophilic lineage, iPA was able to trigger 
the NRF-mediated oxidative response through the induction 
of gene encoding detoxifying and anti-oxidant enzymes—
such as heme oxygenase-1 gene and glutamate-cysteine 
ligase (GCLC)—that protect cells against ROS and reactive 
metabolites. In conclusion, as airway epithelial cells contrib-
ute significantly to airway inflammation in patients with CF 
[34, 36]. The fine tuning of cyto-chemokines secretion by 
iPA along with its ability to improve selenoprotein expres-
sion might be an attractive therapeutic approach to reduce 
excessive airway inflammation which is a major cause of 
CF morbidity.
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